Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.60 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.60 |
| ▸ | VDR | P11473 | 11/20 | 0.55 |
| ▸ | AR | P10275 | 4/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13709349 | 0.85 | HDAC6 (0.66) | HDAC6HDAC3VDRARHDAC1 | |
| SCHEMBL4507917 | 0.84 | HDAC6 (0.67) | HDAC6HDAC3VDRARHDAC1 | |
| SCHEMBL4492612 | 0.84 | HDAC6 (0.61) | HDAC6HDAC3VDRAR | |
| SCHEMBL2968567 | 0.83 | HDAC6 (0.63) | HDAC6HDAC3VDRARHDAC1 | |
| SCHEMBL13709347 | 0.82 | HDAC6 (0.59) | HDAC6HDAC3VDRHDAC1 | |
| SCHEMBL4507047 | 0.82 | HDAC6 (0.61) | HDAC6HDAC3VDR | |
| SCHEMBL2085263 | 0.80 | HDAC3 (0.48) | HDAC6HDAC3VDRAR | |
| SCHEMBL13709366 | 0.80 | VDR (0.57) | HDAC6HDAC3VDRAR | |
| SCHEMBL13709348 | 0.80 | VDR (0.39) | HDAC6HDAC3VDRAR | |
| SCHEMBL13712223 | 0.79 | VDR (0.40) | HDAC6HDAC3VDRAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7595345-B2 | Vitamin D receptor modulators | ELI LILLY AND COMPANY (US) | 2009-09-29 | — | — | US | disclosed |
| US-7595345-B2 | Vitamin D receptor modulators | ELI LILLY AND COMPANY (US) | 2009-09-29 | — | — | US | disclosed |
| US-20080200552-A1 | Vitamin D Receptor Modulators | ELI LILLY AND COMPANY (IN) | 2008-08-21 | — | — | US | disclosed |
| US-20080200552-A1 | Vitamin D Receptor Modulators | ELI LILLY AND COMPANY (IN) | 2008-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200552-A1 | Vitamin D Receptor Modulators | VDR, CYP2R1, CYP24A1 | HDAC6 4464/4885HDAC3 1756/4885VDR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.